Aztreonam/avibactam explained

Type:combo
Component1:Aztreonam
Class1:β-lactam antibiotic
Component2:Avibactam
Class2:β-Lactamase inhibitor
Tradename:Emblaveo
Atc Prefix:None
Legal Eu:Rx-only
Legal Eu Comment:[1]
Kegg:D12889

Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections.[2] [3] [4] Drug resistance to the combination has been reported.[5]

The combination was approved for medical use in the European Union in April 2024.[6]

Medical uses

Aztreonam/avibactam is indicated for the treatment of complicated intra-abdominal infection; hospital-acquired pneumonia, including ventilator-associated pneumonia; or complicated urinary tract infection, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

Society and culture

Legal status

In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emblaveo, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in people with limited treatment options.[7] The applicant for this medicinal product is Pfizer Europe MA EEIG.[8] The combination was approved for medical use in the European Union in April 2024.

Notes and References

  1. Web site: Emblaveo Product information . Union Register of medicinal products . 22 April 2024 . 22 April 2024.
  2. Web site: Pipeline . AbbVie . 25 November 2023 . 25 November 2023 . https://web.archive.org/web/20231125080555/https://www.abbvie.com/science/pipeline.html . live .
  3. Sader . Helio S . Castanheira . Mariana . Kimbrough . John H . Kantro . Valerie . Mendes . Rodrigo E . Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21) . JAC-Antimicrobial Resistance . 22 March 2023 . 5 . 2 . dlad032 . 10.1093/jacamr/dlad032 . 36968952 . 10032302 . 2632-1823.
  4. Livermore . David M. . Mushtaq . Shazad . Vickers . Anna . Woodford . Neil . Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli . International Journal of Antimicrobial Agents . May 2023 . 61 . 5 . 106776 . 10.1016/j.ijantimicag.2023.106776. 36893810 . 257428399 . free .
  5. Nordmann . Patrice . Yao . Yancheng . Falgenhauer . Linda . Sadek . Mustafa . Imirzalioglu . Can . Chakraborty . Trinad . Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany . Antimicrobial Agents and Chemotherapy . 18 October 2021 . 65 . 11 . e0109021 . 10.1128/aac.01090-21. 34424048 . 237268078 . 8522741 .
  6. European Commission Approves Pfizer's Emblaveo for Patients with Multidrug-Resistant Infections and Limited Treatment Options . Pfizer . 22 April 2024 . 22 April 2024.
  7. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024 . European Medicines Agency . 22 March 2024 . 13 June 2024.
  8. Web site: Emblaveo EPAR . European Medicines Agency . 21 March 2024 . 23 March 2024 . 23 March 2024 . https://web.archive.org/web/20240323162104/https://www.ema.europa.eu/en/medicines/human/EPAR/emblaveo . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Aztreonam/avibactam".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.